Wall Street believes that novel hair loss treatments are an untapped gold mine, with a large number of consumers willing to pay out of their own pockets to buy better treatment plans. This is reminiscent of the explosive growth experienced by GLP-1 diet pills. The prospect of a novel treatment plan has driven Veradermics's stock price to rise nearly 500% since it went public in February this year; Absci's stock price has also doubled since this year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.